Tuvirumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | hepatitis B virus |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| (verify) | |
Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B. It has undergone Phase I clinical trials in 2001.[1][2]
References
- ^ Heijtink RA, van Nunen AB, van Bergen P, Ostberg L, Osterhaus AD, de Man RA (August 2001). "Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes". Journal of Medical Virology. 64 (4): 427–34. doi:10.1002/jmv.1068. PMID 11468726. S2CID 28825387.
- ^ van Nunen AB, Baumann M, Manns MP, Reichen J, Spengler U, Marschner JP, de Man RA (June 2001). "Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients". Liver. 21 (3): 207–12. doi:10.1034/j.1600-0676.2001.021003207.x. hdl:1765/66667. PMID 11422784.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |